Search
Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.
Sulfobutylether-beta-cyclodextrin
go.drugbank.com/drugs/DB18607ExperimentalCategories: Compounds used in a research, industrial, or household setting4-Nitrophenyl Phosphate
go.drugbank.com/drugs/DB04214ExperimentalCategories: Compounds used in a research, industrial, or household settingVapreotide
go.drugbank.com/drugs/DB04894InvestigationalVapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
International brands: Sanvar IRPG-530742
go.drugbank.com/drugs/DB05495InvestigationalPG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. … Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Bromodiphenhydramine
go.drugbank.com/drugs/DB01237ApprovedBromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. … Ethanolamine antihistamines produce marked sedation in most patients.
Synonyms: 2-(p-bromo-α-phenylbenzyloxy)-N,N-dimethylethylamineVesnarinone
go.drugbank.com/drugs/DB12082InvestigationalVesnarinone has been used in trials studying the treatment of HIV Infections and Sarcoma, Kaposi.
Categories: Compounds used in a research, industrial, or household settingPR-15
go.drugbank.com/drugs/DB06037InvestigationalPR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.
Alvespimycin
go.drugbank.com/drugs/DB12442InvestigationalAlvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility